HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc., a publicly traded biotechnology company with drug development operations in Houston, Texas (Pink Sheets: BPTH), announced today that Dai-Shan Wong, B.S., RAC and Thomas A. Walker, Ph.D. have joined the Company’s drug development team. Mr. Wong will serve as Bio-Path’s Director of Regulatory Affairs and Quality Assurance. Dr. Walker will be the Company’s Chemistry, Manufacturing and Controls (CMC) Development Specialist. Both will provide strategic and operational expertise for expediting additional regulatory submissions and supervising activities of outside suppliers. Bio-Path is in final stages of preparation for its first Phase 1 clinical study evaluating liposomal Grb-2 in chronic myelogenous leukemia (CML), which will be conducted at The University of Texas M. D. Anderson Cancer Center (“M. D. Anderson”).
